A phase II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for treatment of children with autism spectrum disorder

Dawson et  al have drawn attention to the outcomes of umbilical cord blood (UCB) administration for the treatment of 180 children with autism spectrum disorder (ASD).1 Because there is a substantial interest in stem cell therapy as a potential candidate or therapeutic approach for ASD, these outcomes are not eworthy. The authors provide findings from a large sample size, randomized process with a control group, and processing paradigms, although the results did not support the efficacy of UCB administration.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Letters to the Editor Source Type: research